Development and validation of LC–MS/MS method for amlexanox in rat plasma and its application in preclinical pharmacokinetics. (21st December 2021)

• Record Type: Journal Article
• Authors: Chen, Dan; Du, Kaixin; Niu, Xiaochen; Zhang, Hongwei; Zhang, Xue; Tang, Yu; Zhao, Jianchun
• Is Part Of: Biomedical chromatography. Volume 36:Number 3(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-12-21
• Subjects: amlexanox -- bioavailability -- LC–MS/MS method -- pharmacokinetics; Chromatographic analysis -- Periodicals; Biology -- Periodicals; Medicine -- Periodicals; Biology -- Periodicals; Chromatography -- methods -- Periodicals; Medicine -- Periodicals; 543.089
• DOI: 10.1002/bmc.5288
• Languages: English
• ISSNs: 0269-3879

Abstract

Abstract: Amlexanox, an anti‐inflammatory and anti‐allergic agent, has been widely used clinically for the treatment of canker sores, asthma, and allergic rhinitis. Recently, amlexanox has received considerable attention in curing nonalcoholic fatty liver diseases and hepatitis virus infection. Herein, we first established a sensitive high‐performance liquid chromatography‐tandem mass spectrum (LC–MS/MS) method for the determination of amlexanox in rat plasma. Propranolol was used as the internal standard (IS). Using a simple protein precipitation method, the amlexanox and IS were separated with Capcell Pak C18 column (2.0 × 50 mm, 5 μm) and eluted with water and acetonitrile each containing 0.1% formic acid using gradient elution condition at a flow rate of 0.4 mL·min −1 . Amlexanox and IS were detected by a triple quadrupole mass in multiple reactive monitoring (MRM) under the transitions of m/z 299.2 → 281.2 and m/z 259.9 → 116.1 with positive electrospray ionization, respectively. The calibration curves of amlexanox were established with the range of 50 to 2000 ng·mL −1 (r 2 > 0.99). The validation method consisted of selectivity, accuracy, precision, carryover effect, matrix effect, recovery, dilution effect, and stability. The fully validated method was successfully applied to the pharmacokinetic study of amlexanox in Wistar rats.